| Title： | Left atrial appendage intervention to prevent thromboembolic events in patients with atrial fibrillation: current knowledge and recommendations（2023） |
| Edition： | Updated |
| Classification： | Standard guideline |
| Field： | Diagnosis and Treatment |
| Countries and regions： | China |
| Guidelines users： | clinical physician |
| Evidence classification method： | Level A evidence is defined as evidence from multiple high-quality randomised controlled trials (RCTs) with high consistency of results, high confidence and applicability. Level B evidence is defined as evidence from a single high-quality RCT or multiple low-quality RCTs with high consistency of results, some confidence and applicability. Level C evidence refers to evidence from non-randomised controlled trials, cohort studies, case-control studies, etc, with low consistency of results, low confidence and applicability. Level D evidence refers to evidence from expert opinions, case reports, etc., which have low credibility and applicability. |
| Development unit： | Chinese Society of Pacing and Electrophysiology，Working Committee on Occlusion of left Atrial appendage in Cardiology Professional Committee of Chinese Society of Arrhythmias |
| Registration time: | 2023-09-21 |
| Registration number： | PREPARE-2023CN746 |
| Purpose of the guideline: | The LAA intervention strategy is recommended for the prevention of thromboembolic events in patients with indicated AF |
